zur Navigation zum Inhalt

Onkologie

Personalisierte Therapie

© Fotolia/crevis
11/2016 Individualität im Computermodell. So verschieden wie jeder Mensch und jeder Tumor, so verschieden sollte auch die Therapie sein. Die personalisierte Medizin ist die Antwort auf diese Individualität.

„Jeder Patient ist verschieden, jeder Tumor ist einzigartig“, betonte Prof. [...]

Preface

11/2016 Dear Colleagues,

According to an estimate by the World Health Organization, 1.37 million people worldwide die of lung cancer every year. Both incidence and lung-cancer–related mortality are substantial: to date, primary lung cancer remains the most common malignancy after nonmelanocytic skin cancer, and the global numbers of patients dying from it exceed those linked to any other malignancy. [...]

No phase III benefit with selumetinib in KRAS-mutant NSCLC

11/2016 Oncogenic mutations of _KRAS_ define the largest genomic subset of NSCLC (FIGURE). This patient group appears to derive less clinical benefit from chemotherapy than the overall NSCLC population. There are currently no targeted treatments specifically for patients with _KRAS_-mutant tumours of the lung. [...]

SCLC: genomic alterations pave the way to targeted approaches

11/2016 Rapid growth and early development of metastatic disease are characteristic of small-cell lung cancer (SCLC), which constitutes approximately 15 % of all lung cancer cases [1]. In limited-stage disease, a cure is possible with chemoradiotherapy. [...]

Rare driver mutations: encouraging results in small patient populations

11/2016 As well as _ALK_ fusion mutations and _EGFR_ mutations, studies of the genetic profiles of patients with NSCLC have identified other mutations that might be used for additional targeted therapies. Among these, _ROS1_ and _RET_ rearrangements both occur in 1 % to 2 % of patients with NSCLC. [...]

EGFR-targeted therapy: at the right time in the right patient

11/2016 Approximately 11 % of Caucasian patients with NSCLC have tumours that harbour _EGFR_ mutations [1], which occur in exons 18, 19, 20 and 21 of the _EGFR_ gene. Common mutations include exon 19 in-frame deletions and the exon 21 Leu858Arg point mutation (L858R) [2]. [...]

Medizin heute

Aktuelle Printausgaben

SCHWERPUNKTE ONKOLOGIE

I-O P-Z